Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM P/E Multiple | -0.5x - -0.5x | -0.5x |
| Selected Fwd P/E Multiple | 0.2x - 0.2x | 0.2x |
| Fair Value | €2.63 - €2.91 | €2.77 |
| Upside | 40.6% - 55.4% | 48.0% |
| Benchmarks | - | Full Ticker |
| Target Group Inc. | - | OTCPK:CBDY |
| Cronos Group Inc. | - | NasdaqGM:CRON |
| Akanda Corp. | - | NasdaqCM:AKAN |
| Medexus Pharmaceuticals Inc. | - | OTCPK:MEDX.F |
| Tilray Brands, Inc. | - | NasdaqGS:TLRY |
| InMed Pharmaceuticals Inc. | - | DB:MWG |
| - | - | - |
| Select Price / LTM EPS Ratio | ||||||||
| Benchmark Companies | ||||||||
| CBDY | CRON | AKAN | MEDX.F | TLRY | MWG | |||
| OTCPK:CBDY | NasdaqGM:CRON | NasdaqCM:AKAN | OTCPK:MEDX.F | NasdaqGS:TLRY | DB:MWG | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | NM- | -48.8% | NM- | NM- | NM- | NM- | ||
| 3Y CAGR | -16.2% | NM- | NM- | NM- | NM- | NM- | ||
| Latest Twelve Months | -838.7% | 132.2% | 12.0% | -26.2% | -792.6% | -36.8% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | -4569.3% | -195.2% | -12796.7% | -7.5% | -101.6% | -967.6% | ||
| Prior Fiscal Year | -8.7% | -80.1% | -876.2% | -0.2% | -31.1% | -192.2% | ||
| Latest Fiscal Year | 2.4% | 34.9% | -390.6% | 2.1% | -266.3% | -166.9% | ||
| Latest Twelve Months | 4.0% | 14.2% | -390.6% | 0.8% | -266.3% | -168.9% | ||
| Current Trading Multiples | ||||||||
| EV / LTM EBITDA | 1.0x | -8.9x | 0.1x | 4.6x | 50.7x | 0.1x | ||
| Price / LTM Sales | 0.2x | 7.4x | 3.7x | 0.6x | 1.6x | 0.6x | ||
| LTM P/E Ratio | -1.6x | 52.1x | -0.9x | 78.4x | -0.6x | -0.3x | ||
| Low | Mid | High | ||||||
| Benchmark LTM P/E Ratio | -1.6x | -0.6x | 78.4x | |||||
| Historical LTM P/E Ratio | -3.1x | -0.7x | -0.2x | |||||
| Selected P/E Multiple | -0.5x | -0.5x | -0.5x | |||||
| (x) LTM Net Income | (8) | (8) | (8) | |||||
| (=) Equity Value | 4 | 4 | 4 | |||||
| (/) Shares Outstanding | 1.2 | 1.2 | 1.2 | |||||
| Implied Value Range | 3.33 | 3.51 | 3.68 | |||||
| FX Rate: USD/EUR | 1.2 | 1.2 | 1.2 | Market Price | ||||
| Implied Value Range (Trading Cur) | 2.86 | 3.01 | 3.16 | 1.87 | ||||
| Upside / (Downside) | 53.1% | 61.2% | 69.2% | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | CBDY | CRON | AKAN | MEDX.F | TLRY | MWG | |
| Value of Common Equity | 1 | 1,003 | 3 | 65 | 1,373 | 3 | |
| (/) Shares Outstanding | 617.0 | 382.9 | 2.3 | 32.3 | 1,098.5 | 1.2 | |
| Implied Stock Price | 0.00 | 2.62 | 1.37 | 2.00 | 1.25 | 2.18 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.16 | |
| Implied Stock Price (Trading Cur) | 0.00 | 2.62 | 1.37 | 2.00 | 1.25 | 1.87 | |
| Trading Currency | USD | USD | USD | USD | USD | EUR | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.16 | |